MENU
+Compare
ALDX
Stock ticker: NASDAQ
AS OF
Dec 24, 02:00 PM (EDT)
Price
$5.28
Change
+$0.23 (+4.55%)
Capitalization
303.82M

ALDX stock forecast, quote, news & analysis

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases... Show more

Industry: #Biotechnology
ALDX
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. ALDX showed earnings on November 05, 2025. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for ALDX with price predictions
Dec 23, 2025

ALDX saw its Stochastic Oscillator recovers from the overbought zone

The Stochastic Oscillator for ALDX moved out of overbought territory on December 19, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 60 similar instances where the indicator exited the overbought zone. In of the 60 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

ALDX moved below its 50-day moving average on December 23, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALDX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ALDX's RSI Indicator exited the oversold zone, of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on December 16, 2025. You may want to consider a long position or call options on ALDX as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ALDX just turned positive on December 17, 2025. Looking at past instances where ALDX's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALDX advanced for three days, in of 254 cases, the price rose further within the following month. The odds of a continued upward trend are .

ALDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 196 cases where ALDX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.169) is normal, around the industry mean (26.864). P/E Ratio (0.000) is within average values for comparable stocks, (51.341). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.882). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (312.120).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ALDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.22B. The market cap for tickers in the group ranges from 58 to 116.51B. VRTX holds the highest valuation in this group at 116.51B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 3%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 56%. BMNDF experienced the highest price growth at 467%, while VTGN experienced the biggest fall at -84%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -4%. For the same stocks of the Industry, the average monthly volume growth was -16% and the average quarterly volume growth was -33%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 81
Price Growth Rating: 54
SMR Rating: 92
Profit Risk Rating: 93
Seasonality Score: 16 (-100 ... +100)
View a ticker or compare two or three
ALDX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of therapeutics for eye diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
131 Hartwell Avenue
Phone
+1 781 761-4904
Employees
10
Web
https://www.aldeyra.com